Enliven Therapeutics, Inc. (ELVN)
Automate Your Wheel Strategy on ELVN
With Tiblio's Option Bot, you can configure your own wheel strategy including ELVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ELVN
- Rev/Share 0.0
- Book/Share 5.76
- PB 3.7448
- Debt/Equity 0.0
- CurrentRatio 21.0648
- ROIC -0.381
- MktCap 1239498394.0
- FreeCF/Share -1.4785
- PFCF -16.7495
- PE -11.3846
- Debt/Assets 0.0
- DivYield 0
- ROE -0.3184
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ELVN | Goldman | -- | Buy | -- | $37 | June 16, 2025 |
| Initiation | ELVN | BTIG Research | -- | Buy | -- | $42 | Dec. 13, 2024 |
| Initiation | ELVN | H.C. Wainwright | -- | Buy | -- | $37 | Sept. 9, 2024 |
News
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Published: June 13, 2025 by: PRNewsWire
Sentiment: Neutral
BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,780,263 shares of Enliven's common stock at a price to the public of $19.659 per pre-funded warrant, which represents the per share public …
Read More
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress
Published: May 14, 2025 by: PRNewsWire
Sentiment: Neutral
Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff Presentation at EHA will include updated data with additional patients and longer treatment duration Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET BOULDER, Colo.
Read More
About Enliven Therapeutics, Inc. (ELVN)
- IPO Date 2020-03-12
- Website https://www.enliventherapeutics.com
- Industry Biotechnology
- CEO Mr. Samuel S. Kintz M.B.A.
- Employees 62